Market Closed -
Nasdaq
01:30:00 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
47.84
USD
|
-4.05%
|
|
+0.42%
|
-20.08%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,956
|
4,332
|
4,603
|
5,718
|
7,093
|
5,803
|
-
|
-
|
Enterprise Value (EV)
1 |
1,747
|
3,770
|
4,173
|
5,259
|
6,835
|
5,383
|
5,092
|
5,211
|
P/E ratio
|
-6.25
x
|
-12.5
x
|
-5.35
x
|
-8.41
x
|
-13.5
x
|
-41.6
x
|
41.2
x
|
13.6
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
17.3
x
|
69.2
x
|
75.8
x
|
17.9
x
|
7.35
x
|
4.97
x
|
3.49
x
|
EV / Revenue
|
-
|
15
x
|
62.7
x
|
69.7
x
|
17.2
x
|
6.82
x
|
4.36
x
|
3.14
x
|
EV / EBITDA
|
-6.07
x
|
-17.7
x
|
-7.8
x
|
-8.87
x
|
-13.3
x
|
-72.6
x
|
14.7
x
|
5.97
x
|
EV / FCF
|
-8.21
x
|
-22.7
x
|
-7.4
x
|
-10.2
x
|
-11.5
x
|
-188
x
|
22.3
x
|
12.1
x
|
FCF Yield
|
-12.2%
|
-4.4%
|
-13.5%
|
-9.8%
|
-8.71%
|
-0.53%
|
4.49%
|
8.27%
|
Price to Book
|
57.2
x
|
21.3
x
|
23.2
x
|
33.7
x
|
36.5
x
|
17
x
|
8.83
x
|
4.24
x
|
Nbr of stocks (in thousands)
|
63,888
|
75,737
|
97,358
|
1,10,576
|
1,18,500
|
1,21,294
|
-
|
-
|
Reference price
2 |
30.62
|
57.20
|
47.28
|
51.71
|
59.86
|
47.84
|
47.84
|
47.84
|
Announcement Date
|
27/02/20
|
25/02/21
|
28/02/22
|
21/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
250.6
|
66.56
|
75.42
|
396.6
|
789.4
|
1,169
|
1,661
|
EBITDA
1 |
-287.8
|
-213.1
|
-534.9
|
-593.1
|
-515.1
|
-74.19
|
346.5
|
873
|
EBIT
1 |
-288
|
-213.7
|
-536.3
|
-594.6
|
-517.1
|
-124.9
|
199.9
|
643.7
|
Operating Margin
|
-
|
-85.27%
|
-805.67%
|
-788.38%
|
-130.39%
|
-15.82%
|
17.11%
|
38.75%
|
Earnings before Tax (EBT)
1 |
-304.7
|
-343
|
-746
|
-651.5
|
-526.5
|
-133.9
|
186.3
|
633
|
Net income
1 |
-304.7
|
-344.9
|
-746.4
|
-652.2
|
-528.6
|
-140.1
|
152.5
|
463.9
|
Net margin
|
-
|
-137.59%
|
-1,121.27%
|
-864.7%
|
-133.29%
|
-17.75%
|
13.05%
|
27.92%
|
EPS
2 |
-4.900
|
-4.590
|
-8.840
|
-6.150
|
-4.450
|
-1.151
|
1.161
|
3.520
|
Free Cash Flow
1 |
-212.8
|
-165.9
|
-564.2
|
-515.3
|
-595.5
|
-28.6
|
228.6
|
431
|
FCF margin
|
-
|
-66.19%
|
-847.66%
|
-683.18%
|
-150.16%
|
-3.62%
|
19.56%
|
25.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
65.98%
|
49.37%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
149.95%
|
92.91%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/02/20
|
25/02/21
|
28/02/22
|
21/02/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
5.65
|
60.29
|
14.38
|
16.32
|
22.06
|
22.66
|
44.85
|
94.97
|
110.4
|
146.4
|
162.8
|
187.2
|
210
|
232.5
|
283.7
|
EBITDA
1 |
-127.7
|
-89.02
|
-128.6
|
-148.2
|
-152.5
|
-163.7
|
-174.7
|
-120
|
-136.6
|
-84.04
|
-54.74
|
-37.07
|
-23.94
|
-6.826
|
-
|
EBIT
1 |
-128
|
-89.4
|
-129
|
-148.6
|
-152.9
|
-164.1
|
-175.1
|
-120.4
|
-137.1
|
-84.52
|
-59.79
|
-38.88
|
-18.18
|
0.8503
|
56.85
|
Operating Margin
|
-2,265.4%
|
-148.28%
|
-897%
|
-910.57%
|
-693.41%
|
-723.88%
|
-390.41%
|
-126.82%
|
-124.17%
|
-57.74%
|
-36.73%
|
-20.76%
|
-8.66%
|
0.37%
|
20.04%
|
Earnings before Tax (EBT)
1 |
-195.6
|
-147.7
|
-137.7
|
-155.5
|
-190.8
|
-167.5
|
-177.5
|
-121.8
|
-140
|
-87.15
|
-55.64
|
-44.56
|
-25.11
|
-6.455
|
55.38
|
Net income
1 |
-195.6
|
-147.9
|
-138.9
|
-156
|
-191.3
|
-166
|
-177.8
|
-122
|
-140.2
|
-88.58
|
-55.6
|
-44.57
|
-25.23
|
-6.71
|
53.81
|
Net margin
|
-3,461.43%
|
-245.37%
|
-966.1%
|
-955.62%
|
-867.2%
|
-732.43%
|
-396.42%
|
-128.5%
|
-127.03%
|
-60.51%
|
-34.16%
|
-23.8%
|
-12.01%
|
-2.89%
|
18.97%
|
EPS
2 |
-2.280
|
-1.610
|
-1.420
|
-1.460
|
-1.750
|
-1.500
|
-1.560
|
-1.020
|
-1.170
|
-0.7300
|
-0.4620
|
-0.3660
|
-0.2065
|
-0.0595
|
0.3814
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
08/11/21
|
28/02/22
|
04/05/22
|
08/08/22
|
07/11/22
|
21/02/23
|
04/05/23
|
31/07/23
|
01/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
209
|
562
|
430
|
459
|
258
|
420
|
711
|
591
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-213
|
-166
|
-564
|
-515
|
-596
|
-28.6
|
229
|
431
|
ROE (net income / shareholders' equity)
|
-312%
|
-289%
|
-370%
|
-354%
|
-290%
|
-42.9%
|
28.8%
|
164%
|
ROA (Net income/ Total Assets)
|
-103%
|
-51.1%
|
-81%
|
-79.4%
|
-68.3%
|
-31.9%
|
2.91%
|
257%
|
Assets
1 |
296.4
|
674.9
|
921.2
|
821
|
774.5
|
438.6
|
5,241
|
180.7
|
Book Value Per Share
2 |
0.5400
|
2.690
|
2.040
|
1.530
|
1.640
|
2.810
|
5.420
|
11.30
|
Cash Flow per Share
2 |
-3.390
|
-2.140
|
-6.670
|
-4.840
|
-5.010
|
-0.5200
|
1.260
|
-
|
Capex
1 |
1.69
|
5.42
|
1.1
|
1.52
|
0.77
|
3.04
|
4.8
|
5.17
|
Capex / Sales
|
-
|
2.16%
|
1.66%
|
2.02%
|
0.19%
|
0.38%
|
0.41%
|
0.31%
|
Announcement Date
|
27/02/20
|
25/02/21
|
28/02/22
|
21/02/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
47.84
USD Average target price
81.54
USD Spread / Average Target +70.45% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.08% | 5.8B | | -3.45% | 87.17B | | +1.97% | 40.1B | | +57.16% | 25.12B | | -14.82% | 15.59B | | -8.82% | 12B | | -16.29% | 11.8B | | -41.58% | 11.8B | | +7.27% | 8.81B | | -10.53% | 8.24B |
Biopharmaceuticals
|